Stephen Doberstein
Director/Board Member at FORTE BIOSCIENCES, INC.
Net worth: - $ as of 30/03/2024
Profile
Stephen K.
Doberstein is an Independent Director at Forte Biosciences, Inc. and Principal at Kahiliholo Consulting LLC.
He previously held positions as Director-Pharmaceutical Target Research at Exelixis, Inc., Vice President-Research at XOMA Corp., Vice President-Research at Five Prime Therapeutics, Inc., and Vice President-Research at Xencor, Inc. He was also the Chief Scientific Fellow & Senior Vice President at Nektar Therapeutics.
He served as an Independent Director at Dicerna Pharmaceuticals, Inc. from 2020 to 2021.
Dr. Doberstein received his undergraduate degree from the University of Delaware and his doctorate from The Johns Hopkins University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
FORTE BIOSCIENCES INC.
-.--% | 18/09/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Stephen Doberstein active positions
| Companies | Position | Start |
|---|---|---|
| FORTE BIOSCIENCES, INC. | Director/Board Member | 11/05/2022 |
| Kahiliholo Consulting LLC | Corporate Officer/Principal | 31/01/2020 |
Former positions of Stephen Doberstein
| Companies | Position | End |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Director/Board Member | 27/12/2021 |
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 29/02/2020 |
| FIVE PRIME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30/09/2008 |
| XENCOR, INC. | Chief Tech/Sci/R&D Officer | 30/06/2004 |
| EXELIXIS, INC. | Corporate Officer/Principal | - |
Training of Stephen Doberstein
| University of Delaware | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| XOMA CORPORATION | Health Technology |
| EXELIXIS, INC. | Health Technology |
| XENCOR, INC. | Health Technology |
| FORTE BIOSCIENCES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
| Kahiliholo Consulting LLC |
- Stock Market
- Insiders
- Stephen Doberstein
